Navigation Links
Research advances quest for HIV-1 vaccine

Scientists have uncovered new information that may help guide design of vaccines for HIV-1, the virus that causes AIDS. A new detailed structural analysis of the complex formed by an anti-HIV antibody called 4E10 and its specific target provides insight into why this particular antibody is so broadly effective, a rare characteristic for HIV discovered thus far. The research is published in the February issue of Immunity.

Vaccination has been a successful strategy for protecting humans from many potentially harmful viruses. However, designing a suitable vaccine for HIV-1 has been a highly challenging and thus far unsuccessful endeavor. HIV-1 is enormously variable and it has been difficult to isolate antibodies that will recognize the many different strains of the virus. The antibody 4E10 was derived from HIV-1 infected patients by Dr. Hermann Katinger in Vienna and is the broadest acting neutralizing antibody against HIV-1 that is currently known. This antibody recognizes a protein called gp41 that is found on the surface of the virus. The gp41 protein is thought to play a key role in mediating entry of HIV-1 into human cells.

A research group led by Drs. Dennis R. Burton and Ian A. Wilson from The Scripps Research Institute in La Jolla, California performed a study examining the detailed molecular structure of the complex formed when 4E10 binds to gp41 and determining how interaction of 4E10 with gp41 influences the virus.

X-ray crystallography was used to determine the structure of the complex formed by association of 4E10 with a peptide fragment that is identical to the section of gp41 that the antibody recognizes. The researchers identified the specific amino acids on gp41 that 4E10 interacts with and the 3D structure adopted by these amino acids. These study results suggest that 4E10 interacts with gp41 at a conserved region very close to the surface of the virus and they reveal some special characteristics of 4E10 that make it unusually effective at targeting this region.

Drs. Burton and Wilson are members of a scientific consortium of laboratories, the International AIDS Vaccine Initiative's Neutralizing Antibody Consortium (IAVI), which is focused on understanding broadly neutralizing antibodies at the molecular level and transferring this knowledge into the design of vaccines capable of stimulating broadly neutralizing antibodies against globally diverse HIV. According to Dr. Wayne Koff, IAVI Sr. VP for Vaccine Research, "Elucidation of the critical features of 4E10 recognition of HIV-1 helps to define potential immunogens able to elicit 4E10-like antibodies. This is an excellent example of the tremendous potential for accelerating HIV vaccine design when scientists from multidisciplinary laboratories come together to tackle a major scientific challenge. "

###

Rosa M.F. Cardoso, Michael B. Zwick, Robyn L. Stanfield, Renate Kunert, James M. Binley, Hermann Katinger, Dennis R. Burton, and Ian A. Wilson: "Broadly Neutralizing Anti-HIV Antibody 4E10 Recognizes a Helical Conformation of a Highly Conserved Fusion-Associated Motif in gp41"

Publishing in Immunity, Volume 22, Number 2, February 2005, pages 163?73. http://www.immunity.com/


'"/>

Source:Cell Press


Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Quantum Dots Research Leads to New Knowledge about Protein Binding in Plants
3. Researchers find how protein allows insects to detect and respond to pheromones
4. Researchers Uncover Key Step In Manufacture of Memory Protein
5. Research on Worms Yields Clues on Aging
6. Researchers reveal the infectious impact of salmon farms on wild salmon
7. Researchers identify target for cancer drugs
8. Weill Cornell Research Reveals Secrets Of Trafficking Within Cells
9. Researchers discover molecule that causes secondary stroke
10. Researchers find missing genes of ancient organism
11. Researchers trace evolution to relatively simple genetic changes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/27/2019)... ... ... Shoreline Biome , a microbiome research company that develops tools for ... CEO and Karen Woodward as its VP of Business Development. , These two ... and expand the company’s sales worldwide. , Prior to joining Shoreline Biome, Bill McKenzie ...
(Date:8/27/2019)... ... August 27, 2019 , ... Advancements with ... This episode is scheduled to broadcast 4Q/2019. Check local listings for more information. ... investment and manufacturing company. The show will highlight how Debiopharm is working to ...
(Date:8/23/2019)... ... August 22, 2019 , ... R121 ... their acquisition in June of 2018. Along with the name change, this rebranding ... “Our goal was to create a cohesive brand that blended our core foundation ...
Breaking Biology News(10 mins):
(Date:9/8/2019)... , ... September 05, 2019 , ... ... Blaine Fitzgerald, former Vice President of Finance for Shopify, has been named Chief ... and healthcare venture capitalist Joel Finlayson as strategic advisors. Additionally, Spartan has hired ...
(Date:8/29/2019)... ... August 28, 2019 , ... DuPont Nutrition ... solutions to attendees at the International Baking Industry Expo, September 8 to 11, ... optimizing production efficiency to cost and waste reduction and from maintaining freshness throughout ...
(Date:8/25/2019)... ... August 23, 2019 , ... ... 1 best-selling status for the scientific research book “Impact of Biofield Treatment on ... and perfume industry as Patchouli. , The book garnered No. 1 status ...
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... ... receptor and in vitro toxicology testing solutions, announced the appointment of Mark McLoughlin ... experience to the Board. , Mark McLoughlin will lend his healthcare expertise and ...
Breaking Biology Technology: